BioLight Life Sciences Ltd
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination… Read more
BioLight Life Sciences Ltd (BOLT) - Total Assets
Latest total assets as of June 2025: ILA26.67 Million ILA
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) holds total assets worth ILA26.67 Million ILA as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioLight Life Sciences Ltd - Total Assets Trend (2005–2024)
This chart illustrates how BioLight Life Sciences Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioLight Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
BioLight Life Sciences Ltd's total assets of ILA26.67 Million consist of 42.0% current assets and 58.0% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 28.5% |
| Accounts Receivable | ILA435.00K | 1.3% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA686.00K | 2.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how BioLight Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLight Life Sciences Ltd's current assets represent 42.0% of total assets in 2024, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 28.5% of total assets in 2024, up from 11.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 2.0% of total assets.
BioLight Life Sciences Ltd Competitors by Total Assets
Key competitors of BioLight Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BioLight Life Sciences Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioLight Life Sciences Ltd generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioLight Life Sciences Ltd is currently not profitable relative to its asset base.
BioLight Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 4.39 | 13.49 |
| Quick Ratio | 4.49 | 4.39 | 13.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA6.71 Million | ILA 10.87 Million | ILA 50.03 Million |
BioLight Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between BioLight Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.52 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | ILA34.12 Million |
| Market Capitalization | $82.11K USD |
Valuation Analysis
Below Book Valuation: The market values BioLight Life Sciences Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BioLight Life Sciences Ltd's assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BioLight Life Sciences Ltd (2005–2024)
The table below shows the annual total assets of BioLight Life Sciences Ltd from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA34.12 Million | +2.00% |
| 2023-12-31 | ILA33.45 Million | -41.32% |
| 2022-12-31 | ILA57.01 Million | -11.16% |
| 2021-12-31 | ILA64.17 Million | -1.01% |
| 2020-12-31 | ILA64.83 Million | -13.50% |
| 2019-12-31 | ILA74.95 Million | -16.98% |
| 2018-12-31 | ILA90.28 Million | +264.58% |
| 2017-12-31 | ILA24.76 Million | -29.88% |
| 2016-12-31 | ILA35.31 Million | -44.19% |
| 2015-12-31 | ILA63.27 Million | +56.48% |
| 2014-12-31 | ILA40.43 Million | +17.77% |
| 2013-12-31 | ILA34.33 Million | -18.04% |
| 2012-12-31 | ILA41.89 Million | +41.37% |
| 2011-12-31 | ILA29.63 Million | +192.26% |
| 2010-12-31 | ILA10.14 Million | -54.92% |
| 2009-12-31 | ILA22.49 Million | -53.31% |
| 2006-12-31 | ILA48.16 Million | +136.21% |
| 2005-12-31 | ILA20.39 Million | -- |